Literature DB >> 15261277

Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.

Shudong Wang1, Gavin Wood, Christopher Meades, Gary Griffiths, Carol Midgley, Iain McNae, Campbell McInnes, Sian Anderson, Wayne Jackson, Mokdad Mezna, Rhoda Yuill, Malcolm Walkinshaw, Peter M Fischer.   

Abstract

A series of 2-anilino-4-(1H-pyrrol-3-yl)pyrimidines were prepared and evaluated for their ability to inhibit cyclin-dependent kinases (CDKs). A number of analogues were found to be potent CDK2 and CDK4 inhibitors and to exhibit anti-proliferative activity against human tumour cell lines. Structure-activity relationships and biochemical characterization are presented.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15261277     DOI： 10.1016/j.bmcl.2004.06.012

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  8 in total

Review 1.  Ligand discovery and virtual screening using the program LIDAEUS.

Authors:  P Taylor; E Blackburn; Y G Sheng; S Harding; K-Y Hsin; D Kan; S Shave; M D Walkinshaw
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

2.  Synthesis and anti-breast cancer activity of novel indibulin related diarylpyrrole derivatives.

Authors:  Ebrahim Saeedian Moghadam; Ernest Hamel; Zahra Shahsavari; Mohsen Amini
Journal:  Daru       Date:  2019-03-20       Impact factor: 3.117

3.  In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83.

Authors:  Xiangrui Liu; Frankie Lam; Shenhua Shi; Peter M Fischer; Shudong Wang
Journal:  Invest New Drugs       Date:  2011-02-18       Impact factor: 3.850

4.  Revisit to the synthesis of 1,2,3,4-tetrasubstituted pyrrole derivatives in lactic acid media as a green solvent and catalyst.

Authors:  Dilek Akbaslar; E Sultan Giray; Oztekin Algul
Journal:  Mol Divers       Date:  2020-09-27       Impact factor: 2.943

5.  NEK1 kinase domain structure and its dynamic protein interactome after exposure to Cisplatin.

Authors:  Talita D Melo-Hanchuk; Priscila Ferreira Slepicka; Gabriela Vaz Meirelles; Fernanda Luisa Basei; Diogo Ventura Lovato; Daniela Campos Granato; Bianca Alves Pauletti; Romenia Ramos Domingues; Adriana Franco Paes Leme; Alessandra Luiza Pelegrini; Guido Lenz; Stefan Knapp; Jonathan M Elkins; Jörg Kobarg
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

6.  Synthesis of Pyrimidine- and Quinazoline-Fused Benzimidazole-4,7-diones Using Combinatorial Cyclocondensation and Oxidation.

Authors:  Dong Young Kim; Pham Duy Quang Dao; Chan Sik Cho
Journal:  ACS Omega       Date:  2018-12-17

7.  Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.

Authors:  Alison J Hole; Sonja Baumli; Hao Shao; Shenhua Shi; Shiliang Huang; Chris Pepper; Peter M Fischer; Shudong Wang; Jane A Endicott; Martin E Noble
Journal:  J Med Chem       Date:  2013-01-29       Impact factor: 7.446

8.  Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.

Authors:  Hao Shao; Shenhua Shi; Shiliang Huang; Alison J Hole; Abdullahi Y Abbas; Sonja Baumli; Xiangrui Liu; Frankie Lam; David W Foley; Peter M Fischer; Martin Noble; Jane A Endicott; Chris Pepper; Shudong Wang
Journal:  J Med Chem       Date:  2013-01-25       Impact factor: 7.446
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.